Lattice Biologics (Lattice Biologics) EBIT per Share : $-0.00 (TTM As of Jun. 2021)

View and export this data going back to 2001. Start your Free Trial

What is Lattice Biologics EBIT per Share?

Lattice Biologics's EBIT per Share for the three months ended in Jun. 2021 was $0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2021 was $-0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Lattice Biologics's EBIT per Share or its related term are showing as below:

LBLTF's 3-Year EBIT Growth Rate is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 5.9
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Lattice Biologics's EBIT for the three months ended in Jun. 2021 was $-0.03 Mil.

Lattice Biologics EBIT per Share Historical Data

The historical data trend for Lattice Biologics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lattice Biologics EBIT per Share Chart

Lattice Biologics Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Sep16

Sep17

Sep18

Sep19

Sep20

EBIT per Share

Get a 7-Day Free Trial

-0.14

-0.01

Lattice Biologics Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
EBIT per Share	Get a 7-Day Free Trial															-	-	-	-	-

Lattice Biologics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Lattice Biologics's EBIT per Share for the fiscal year that ended in Sep. 2020 is calculated as

	EBIT per Share		(A: Sep. 2020 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.442	/	102.576
=	-0.00

Lattice Biologics's EBIT per Share for the quarter that ended in Jun. 2021 is calculated as

	EBIT per Share		(Q: Jun. 2021 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.026	/	128.218
=	-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00

Lattice Biologics (OTCPK:LBLTF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Lattice Biologics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Lattice Biologics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Lattice Biologics (Lattice Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lattice Biologics Ltd (OTCPK:LBLTF) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714

Website

http://www.latticebiologics.com

Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The products of the company include ADM dermis, DBM Putty, Bone scaffold, and Others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.

Lattice Biologics (Lattice Biologics) Headlines

No Headlines